Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IDXX
IDXX logo

IDXX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
590.245
Open
585.900
VWAP
585.23
Vol
254.49K
Mkt Cap
46.80B
Low
581.630
Amount
148.94M
EV/EBITDA(TTM)
31.54
Total Shares
79.42M
EV
47.47B
EV/OCF(TTM)
40.17
P/S(TTM)
11.09
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.
Show More

Events Timeline

(ET)
2026-04-01
05:20:00
Idexx Laboratories Launches Cancer Dx Panel in the UK
select
2026-02-02 (ET)
2026-02-02
06:40:00
IDEXX Reports Q4 Revenue of $1.09B
select

News

Yahoo Finance
5.0
04-11Yahoo Finance
IDEXX Launches Canine Cancer Detection Panel in the UK
  • Early Detection Innovation: IDEXX's newly launched cancer detection panel in the UK is specifically designed for early detection of lymphoma in at-risk dogs, providing results within 3 to 5 business days, which addresses a critical clinical need and is expected to significantly enhance diagnostic efficiency for veterinarians.
  • Strong Market Demand: Data indicates that 71% of UK pet owners have expressed interest in cancer screening for their pets, reflecting robust market demand for this test and further driving IDEXX's market share growth in the veterinary field.
  • Significant Technical Advantages: The panel offers 79% sensitivity and 99% specificity, enabling classification of B-cell and T-cell phenotypes while also allowing monitoring of patients during chemotherapy, thereby enhancing veterinarians' decision-making capabilities in cancer management.
  • Future Expansion Plans: IDEXX plans to expand the panel's capabilities over the next three years to cover the majority of canine cancer cases, further solidifying its leadership position in proactive veterinary cancer management and intervention.
Newsfilter
9.5
04-08Newsfilter
IDEXX Laboratories Schedules Q1 2026 Financial Results Release
  • Earnings Release Schedule: IDEXX Laboratories has scheduled the release of its Q1 2026 financial results for May 5, 2026, before market open, demonstrating the company's commitment to transparency and investor communication.
  • Analyst Conference Call: The company will host an analyst conference call at 8:30 AM ET on the same day, providing an interactive opportunity for investors to gain insights into the company's performance and build confidence.
  • Webcast Access: Investors can access the live webcast and Q1 2026 Earnings Snapshot through the IDEXX website, ensuring broad dissemination and availability of information, which enhances the company's transparency.
  • Global Impact: As a leader in pet healthcare innovation, IDEXX is dedicated to supporting the veterinary community through its diagnostic and software products, advancing medical care and improving efficiency, thereby reinforcing its significant position in the industry.
Yahoo Finance
9.5
04-08Yahoo Finance
IDEXX Laboratories to Release Q1 2026 Financial Results
  • Earnings Release Schedule: IDEXX Laboratories has scheduled its Q1 2026 financial results release for May 5, 2026, before market open, indicating the company's commitment to transparency and investor communication.
  • Analyst Conference Call: The company will hold an analyst conference call at 8:30 a.m. ET on the same day, providing a real-time platform for engagement to enhance investor confidence.
  • Webcast Access: Investors can access the live webcast and Q1 earnings snapshot through the IDEXX website, ensuring timely information dissemination and enhancing the company's credibility among investors.
  • Long-term Replay Availability: The archived version of the call will be available for one year post-event, demonstrating IDEXX's commitment to ongoing communication and information transparency.
Newsfilter
5.0
04-01Newsfilter
IDEXX Launches Canine Cancer Detection Panel in the UK
  • Early Detection Innovation: The IDEXX Cancer Dx Panel launched in the UK provides results within 3-5 business days at a starting price of £22.50, enabling veterinarians to identify lymphoma in at-risk dogs sooner, thereby improving treatment success rates and enhancing the quality of life for affected pets.
  • Strong Market Demand: Research indicates that 71% of pet owners in the UK are interested in cancer screening tests, signaling a growing demand for proactive health management, which IDEXX's product is poised to meet, potentially driving growth in the pet healthcare sector.
  • Integration Advantages: The test seamlessly integrates into existing veterinary workflows, allowing veterinarians to conduct multiple tests with a single blood draw, simplifying operations and enhancing efficiency, thereby reinforcing IDEXX's leadership position in the veterinary diagnostics market.
  • Future Expansion Plans: IDEXX plans to expand the Cancer Dx Panel to cover most canine cancer cases over the next three years, aiming to transform cancer detection methods through early intervention and elevate overall pet health management standards.
CNBC
7.5
03-29CNBC
Employers Recognize Employee Pet Care Needs
  • Emerging Employee Trend: As U.S. companies mandate a full return to office, pet care is increasingly recognized as a vital short-term support service, with approximately 59 million Americans providing family care in 2024, highlighting the strong demand for pet care.
  • Significant Absenteeism Impact: A survey by Wagmo reveals that 75% of pet owners missed work due to pet care issues in the past year, with 26% missing six or more days, indicating a direct impact on employee productivity.
  • Expanded Corporate Benefits: Wellthy introduced pet care into its back-up services in 2024, with around 50% of clients offering this benefit, showcasing innovation and adaptability in employee welfare aimed at enhancing satisfaction and retention rates.
  • Context of Caregiving Crisis: While pet care may not be the most urgent need, Wellthy's service expansion aligns with the founder's personal caregiving experiences, aiming to alleviate financial and emotional stress for families, thereby improving overall workplace productivity.
NASDAQ.COM
2.0
03-19NASDAQ.COM
Analysis of the Importance of Market Capitalization
  • Market Capitalization Comparison: Dell Technologies Inc (DELL) has a market cap of $47.50 billion, while Idexx Laboratories, Inc. (IDXX) stands at $45.95 billion, providing investors with a more accurate assessment of company value and avoiding misconceptions based solely on stock price.
  • Investor Decision Impact: Market capitalization not only affects a company's size ranking among peers but also directly influences which mutual funds and ETFs are willing to hold these stocks, as large-cap funds may focus solely on companies valued at over $10 billion.
  • Mid-Cap Performance Potential: The S&P MidCap index focuses on smaller companies by excluding the largest 100 firms, allowing mid-cap stocks to potentially outperform larger rivals in favorable market conditions, thus offering additional investment opportunities for investors.
  • Price Performance Comparison: At Thursday's close, DELL's stock rose approximately 5.1%, while IDXX's stock increased by about 0.5%, indicating Dell's strong market performance, which may attract more investor attention to its growing market capitalization.
Wall Street analysts forecast IDXX stock price to rise
10 Analyst Rating
Wall Street analysts forecast IDXX stock price to rise
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
750.00
Averages
792.78
High
850.00
Current: 0.000
sliders
Low
750.00
Averages
792.78
High
850.00
Citi
Daniel Grosslight
Neutral
initiated
$650
AI Analysis
2026-04-15
New
Reason
Citi
Daniel Grosslight
Price Target
$650
AI Analysis
2026-04-15
New
initiated
Neutral
Reason
Citi analyst Daniel Grosslight initiated coverage of Idexx Laboratories with a Neutral rating and $650 price target. The firm launched the animal health and dental sectors with a "cautiously optimistic" view. Citi favors the animal health group, saying the the "humanization" pet trend is real and should drive more spending. The firm's top pick is Zoetis. It sees the weak macro backdrop pressuring the dental sector. Citi expects a trade-down to lower cost implants and orthodontics. Citi's top dental pick is Henry Schein.
Stifel
Jonathan Block
Buy
downgrade
$775 -> $675
2026-03-31
Reason
Stifel
Jonathan Block
Price Target
$775 -> $675
2026-03-31
downgrade
Buy
Reason
Stifel analyst Jonathan Block lowered the firm's price target on Idexx Laboratories to $675 from $775 and keeps a Buy rating on the shares. The firm continues to view Idexx as more of a second half story, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IDXX
Unlock Now

Valuation Metrics

The current forward P/E ratio for IDEXX Laboratories Inc (IDXX.O) is 40.32, compared to its 5-year average forward P/E of 49.72. For a more detailed relative valuation and DCF analysis to assess IDEXX Laboratories Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
49.72
Current PE
40.32
Overvalued PE
61.67
Undervalued PE
37.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
34.61
Current EV/EBITDA
29.83
Overvalued EV/EBITDA
42.77
Undervalued EV/EBITDA
26.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
11.08
Current PS
8.93
Overvalued PS
13.50
Undervalued PS
8.65

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top stocks in health sector
Intellectia · 38 candidates
Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
866.87B
ABBV logo
ABBV
AbbVie Inc
364.65B
AZN logo
AZN
AstraZeneca PLC
293.00B
MRK logo
MRK
Merck & Co Inc
282.35B
UNH logo
UNH
UnitedHealth Group Inc
254.55B
AMGN logo
AMGN
Amgen Inc
188.63B
what is a good buy right now
Intellectia · 32 candidates
Analyst Consensus: Strong Buy, Moderate BuyQuarter Eps Yoy Growth: 15.0% - 100.0%Target Price Upside Potential: MoreAbovePrice, AbovePriceIs Index Component: GSPC, NDXOne Week Rise Prob: 60 - 100One Week Predict Return: 0.0% - 100.0%
Ticker
Name
Market Cap$
top bottom
TPR logo
TPR
Tapestry Inc
26.06B
BK logo
BK
Bank of New York Mellon Corp
81.14B
TTD logo
TTD
Trade Desk Inc
13.04B
GPN logo
GPN
Global Payments Inc
18.87B
MDB logo
MDB
MongoDB Inc
27.39B
MA logo
MA
Mastercard Inc
492.21B
which stock price above $100 but bearish
Intellectia · 61 candidates
Price: >= $100.00Option Sentiments: Bearish
Ticker
Name
Market Cap$
top bottom
TSM logo
TSM
Taiwan Semiconductor Manufacturing Co Ltd
1.69T
MA logo
MA
Mastercard Inc
473.76B
GE logo
GE
General Electric Co
335.96B
KLAC logo
KLAC
KLA Corp
199.72B
BLK logo
BLK
BlackRock Inc
183.61B
GEV logo
GEV
GE Vernova Inc
181.21B

Whales Holding IDXX

L
Los Angeles Capital Management LLC
Holding
IDXX
+47.13%
3M Return
L
Liontrust Asset Management PLC
Holding
IDXX
+11.59%
3M Return
I
Inspire Investing, LLC
Holding
IDXX
+11.35%
3M Return
B
Bank Pictet & Cie (Europe) AG
Holding
IDXX
+9.86%
3M Return
C
Congress Asset Management Company, LLP
Holding
IDXX
+8.25%
3M Return
A
Amundi Luxembourg S.A.
Holding
IDXX
+7.51%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is IDEXX Laboratories Inc (IDXX) stock price today?

The current price of IDXX is 583.81 USD — it has decreased -0.92

What is IDEXX Laboratories Inc (IDXX)'s business?

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.

What is the price predicton of IDXX Stock?

Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is792.78 USD with a low forecast of 750.00 USD and a high forecast of 850.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IDEXX Laboratories Inc (IDXX)'s revenue for the last quarter?

IDEXX Laboratories Inc revenue for the last quarter amounts to 1.09B USD, increased 14.28

What is IDEXX Laboratories Inc (IDXX)'s earnings per share (EPS) for the last quarter?

IDEXX Laboratories Inc. EPS for the last quarter amounts to 3.08 USD, increased 17.56

How many employees does IDEXX Laboratories Inc (IDXX). have?

IDEXX Laboratories Inc (IDXX) has 11000 emplpoyees as of April 20 2026.

What is IDEXX Laboratories Inc (IDXX) market cap?

Today IDXX has the market capitalization of 46.80B USD.